236 related articles for article (PubMed ID: 24289070)
21. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
Irwin N; Montgomery IA; Moffett RC; Flatt PR
Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
[TBL] [Abstract][Full Text] [Related]
22. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
[TBL] [Abstract][Full Text] [Related]
23. Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice.
Irwin N; McClean PL; Harriott P; Flatt PR
Exp Gerontol; 2007 Apr; 42(4):296-300. PubMed ID: 17184947
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
[TBL] [Abstract][Full Text] [Related]
25. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
26. Bilirubin Increases Insulin Sensitivity by Regulating Cholesterol Metabolism, Adipokines and PPARγ Levels.
Liu J; Dong H; Zhang Y; Cao M; Song L; Pan Q; Bulmer A; Adams DB; Dong X; Wang H
Sci Rep; 2015 May; 5():9886. PubMed ID: 26017184
[TBL] [Abstract][Full Text] [Related]
27. Alteration of sweet taste in high-fat diet induced obese rats after 4 weeks treatment with exenatide.
Zhang XJ; Wang YQ; Long Y; Wang L; Li Y; Gao FB; Tian HM
Peptides; 2013 Sep; 47():115-23. PubMed ID: 23891652
[TBL] [Abstract][Full Text] [Related]
28. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Diabetes Obes Metab; 2011 Jan; 13(1):26-33. PubMed ID: 21114600
[TBL] [Abstract][Full Text] [Related]
30. Chronic central leptin decreases food intake and improves glucose tolerance in diet-induced obese mice independent of hypothalamic malonyl CoA levels and skeletal muscle insulin sensitivity.
Keung W; Palaniyappan A; Lopaschuk GD
Endocrinology; 2011 Nov; 152(11):4127-37. PubMed ID: 21914780
[TBL] [Abstract][Full Text] [Related]
31. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
[TBL] [Abstract][Full Text] [Related]
32. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice.
Camacho RC; Zafian PT; Achanfuo-Yeboah J; Manibusan A; Berger JP
Eur J Pharmacol; 2013 Sep; 715(1-3):41-5. PubMed ID: 23831019
[TBL] [Abstract][Full Text] [Related]
33. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.
Shang Q; Saumoy M; Holst JJ; Salen G; Xu G
Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G419-24. PubMed ID: 20044510
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
[TBL] [Abstract][Full Text] [Related]
35. Peptide-YY
Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
[TBL] [Abstract][Full Text] [Related]
36. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
[TBL] [Abstract][Full Text] [Related]
37. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1.
Cani PD; Neyrinck AM; Maton N; Delzenne NM
Obes Res; 2005 Jun; 13(6):1000-7. PubMed ID: 15976142
[TBL] [Abstract][Full Text] [Related]
38. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
[TBL] [Abstract][Full Text] [Related]
39. Selective FFA2 Agonism Appears to Act via Intestinal PYY to Reduce Transit and Food Intake but Does Not Improve Glucose Tolerance in Mouse Models.
Forbes S; Stafford S; Coope G; Heffron H; Real K; Newman R; Davenport R; Barnes M; Grosse J; Cox H
Diabetes; 2015 Nov; 64(11):3763-71. PubMed ID: 26239054
[TBL] [Abstract][Full Text] [Related]
40. Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Pandey D; Patel H; Ranvir R; Kadam S; Patel D; Bahekar R; Jain M
Chem Biol Interact; 2018 Feb; 282():13-21. PubMed ID: 29325849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
